Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 16/20 | 0.64 |
| ▸ | DYRK1B | Q9Y463 | 13/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10446582 | 0.93 | DYRK1A (0.67) | DYRK1ADYRK1BFGFR1FGFR2FGFR4 | |
| SCHEMBL10446965 | 0.90 | DYRK1A (0.68) | DYRK1ADYRK1B | |
| SCHEMBL10446540 | 0.90 | DYRK1A (0.72) | DYRK1ADYRK1B | |
| SCHEMBL10446561 | 0.89 | DYRK1A (0.68) | DYRK1ADYRK1B | |
| Hydrochloric Acid SCHEMBL10322671 | 0.88 | DYRK1A (0.67) | DYRK1ADYRK1B | |
| SCHEMBL10446547 | 0.87 | DYRK1A (0.72) | DYRK1ADYRK1B | |
| SCHEMBL10322930 | 0.86 | DYRK1A (0.74) | DYRK1ADYRK1B | |
| SCHEMBL10446722 | 0.86 | DYRK1A (0.69) | DYRK1ADYRK1B | |
| SCHEMBL10324245 | 0.84 | DYRK1A (0.66) | DYRK1ADYRK1B | |
| SCHEMBL10324361 | 0.81 | DYRK1A (0.73) | DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | DYRK1A 654/4885DYRK1B 570/4885KMT2A 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.